Manufacturers face several challenges with the LAL test, including test accuracy issues such as false positives/negatives and the low endotoxin recovery phenomenon that can mask contamination, reagent supply constraints due to horseshoe crab population decline and import reliance in markets like China, high costs and validation burdens when switching to recombinant alternatives, and regulatory divergence across pharmacopoeias requiring redundant validation for global submissions.











